• 1
    Llovet J, Real MI, Montana X, Planas R, Coll S, Aponte J, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Lancet 2002; 359: 17341739.
  • 2
    Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35: 11641171.
  • 3
    Poon RT, Fan S, Tsang FH, Wong J. Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeon's perspective. Ann Surg 2002; 235(4): 466486.
  • 4
    Curley SA, Izzo F, Ellis LM, Vauthey JN, Vallone P. Radiofrequency ablation of hepatocellular carcinoma in 110 patients with cirrhosis. Ann Surg 2000; 232: 381391.
  • 5
    Wood TF, Rose DM, Chung M, Allegra DP, Foshag LJ, Bilchik AJ. Radiofrequency ablation of 231 unresectable hepatic tumors: indications, limitations, and complications. Ann Surg Oncol 2000; 7: 593600.
  • 6
    Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999; 3: 14341440.
  • 7
    Yao FY, Bass NM, Nikolai B, Davern TJ Kerlan R, Wu V, et al. Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and drop-out from the waiting list. Liver Transpl 2002; 8: 873883.
  • 8
    Graziadei IW, Sandmueller H, Waldenberger P, Koenigsrainer A, Nachbaur K, Jaschke W, et al. Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome. Liver Transpl 2003; 9: 557563.
  • 9
    Johnson EW, Holck PS, Levy AE, Yeh MM, Yeung RS. The role of tumor ablation in bridging patients to liver transplantation. Arch Surg 2004; 139: 825830.
  • 10
    Yao FY, Bass NM, Nikolai B, Merriman R, Davern TJ, Kerlan R, et al. A follow-up analysis of the pattern and predictors of dropout from the waiting list for liver transplantation in patients with hepatocellular carcinoma: implication for the current organ allocation policy. Liver Transpl 2003; 9: 684692.
  • 11
    Majno PE, Adam R, Bismuth H, Castaing D, Ariche A, Krissat J, et al. Influence of preoperative transarterial lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis. Ann Surg 1997; 226: 688703.
  • 12
    Yao FY, Kinkhabwala M, LaBerge JM, Bass NM, Brown Jr.R, Kerlan R, et al. The impact of pre-operative loco-regional therapy on outcome after liver transplantation for Hepatocellular carcinoma. Am J Transpl 2005; 5: 795804.
  • 13
    Livraghi T, Goldberg SN, Lazzaroni S, Meloni F, Ierace T, Solbiati L, et al. Hepatocellular carcinoma: radiofrequency ablation of medium and large lesions. Radiology 2000; 214: 761768.
  • 14
    Livraghi T, Goldberg SN, Lazzaroni S, Meloni F, Solbiati L, Gazelle GS. Small hepatocellular carcinoma: Treatment with radio-frequency ablation versus ethanol injection. Radiology 1999; 210: 655661.
  • 15
    Sironi S, Libraghi T, Meloni F, De Cobelli F, Ferrero CG, Del Maschio A. Small hepatocellular carcinoma treated with percutaneous RF ablation: MR imaging follow-up. AJR Am J Roentgenol 1999; 173: 12251229.
  • 16
    Morimoto M, Sugimori K, Shirato K, Kokawa A, Tomita N, Saito T, et al. Treatment of hepatocellular carcinoma with radiofrequency ablation: radiology-histologic correlation during follow-up periods. Hepatology 2002; 35: 14671475.
  • 17
    Spreafico C, Marchiano A, Regalia E, Frigerio LF, Garbagnati F, Andreola S, et al. Chemoembolization of hepatocellular carcinoma in patients who undergo liver transplantation. Radiology 1994; 192: 687690.
  • 18
    Hoffman AL, Wu SS, Obaid AK, French SW, Lois J, McMonigle M, et al. Histologic evaluation and treatment outcome after sequential radiofrequency ablation and hepatic resection for primary and metastatic tumors. Am Surg 2002; 68: 10281043.
  • 19
    Mazzaferro V, Battiston C, Perrone S, Pulvirenti A, Regalia E, Romito R, et al. Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: a prospective study. Ann Surg 2004; 240: 900909.
  • 20
    Fontana RJ, Hamidullah H, Nghiem H, Greenson JK, Hussain H, Marrero J, et al. Percutaneous radiofrequency thermal ablation of hepatocellular carcinoma: a safe and effective bridge to liver transplantation. Liver Transpl 2002; 8: 11651174.
  • 21
    Oldhafer KJ, Ajay C, Fruhauf NR, Flemming P, Schlitt HJ, Kubicka S, et al. Arterial chemoembolization before liver transplantation in patients with hepatocellular carcinoma: marked tumor necrosis, but no survival benefit? J Hepatol 1998; 29: 953959.
  • 22
    Bloomston M, Binitie O, Fraiji E, Murr M, Zervos E, Goldin S, et al. Transcatheter arterial chemoembolization with or without radiofrequency ablation in the management of patients with advanced hepatic malignancy. Am Surg 2002; 68: 8271071.
  • 23
    Yamakado K, Nakatsuka A, Ohmori S, Shiraki K, Nakano T, Ikoma J, et al. Radiofrequency ablation combined with chemoembolization in hepatocellular carcinoma: treatment response based on tumor size and morphology. J Vasc Interv Radiol 2002; 13: 12251232.
  • 24
    Veltri A, Grosso M, Martina MC, Ciancio A, David E, Salizzoni M, et al. Effect of preoperative radiological treatment of hepatocellular carcinoma before liver transplantation: a retrospective study. Cardiovasc Intervent Radiol 1998; 21: 393398.
  • 25
    Sheu JC, Sung JL, Chen DS, Yang PM, Lai MY, Lee CS, et al. Growth rate of asymptomatic hepatocellular carcinoma and its clinical implications. Gastroenterology 1985; 89: 259266.
  • 26
    United Network for Organ Sharing. Based on OPTN data of September 2004. Katarina Anderson: Systems analyst.
  • 27
    Sharma P, Balan V, Hernandez JL, Harper AM, Edwards EB, Rodriguez-Luna H, et al. Liver transplantation for hepatocellular carcinoma: the MELD impact. Liver Transpl 2004; 10: 3641.
  • 28
    Wiesner RH, Freeman RB, Mulligan DC. Liver transplantation for hepatocellular cancer: the impact of the MELD allocation policy. Gastroenterology 2004; 127: S2617
  • 29
    Mithoefer A, Harper A, Edwards E, Schore A, Freeman R. HCC prioritization changes do not result in more advanced HCC at transplant. Am J Transpl 2005; 5(Suppl 11): 427.
  • 30
    Yao FY, Bass NM, Ascher NL, and Roberts JP. Liver transplantation for hepatocellular carcinoma: lessons from the first year under the model of end-stage liver disease (MELD) organ allocation policy. Liver Transpl 2004; 10: 621630.
  • 31
    Edmondson H, Steiner P. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer 1954; 7: 462503.
  • 32
    Rosen MA, Hochhold J, Olthoff KM, Furth EE, Shetty K, Reddy KR, et al. Staging accuracy of MRI for HCC in a liver transplant population. Am J Transpl 2005; 5, Suppl 11: 235.
  • 33
    Llovet JM, Mas X, Aponte JJ, Fuster J, Navasa M, Christensen E, et al. Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation. Gut 2002; 50: 123128.